Show simple item record Szegedi, Márta Molnár, Mária Judit Boncz, Imre Kosztolányi, György 2016-06-29T17:08:10Z 2016-06-29T17:08:10Z 2014
dc.identifier 84925581911
dc.identifier.citation pagination=1735-1741; journalVolume=155; journalIssueNumber=44; journalTitle=ORVOSI HETILAP;
dc.identifier.uri doi:10.1556/OH.2014.30031
dc.description.abstract Focusing on the benefits of patients with rare disease the authors analysed the aspects of orphan medicines financed in the frame of the Hungarian social insurance system in 2012 in order to make the consumption more rational, transparent and predictable. Most of the orphan drugs were financed in the frame of compassionate use by the reimbursement system. Consequently, a great deal of crucial problems occurred in relation to the unconventional subsidized method, especially in the case of the highest cost enzyme replacement therapies. On the base of the findings, proposals of the authors are presented for access to orphan drugs, fitting to the specific professional, economical and ethical aspects of this unique field of the health care system. The primary goal is to provide a suitable subsidized method for the treatment of rare disease patients with unmet medical needs. The financial modification of orphans became indispensible in Hungary. Professionals from numerous fields dealing with rare disease patients' care expressed agreement on the issue. Transforming the orphan medicines' financial structure has been initiated according to internationally shared principles. Orv. Hetil., 2014, 155(44), 1735-1741.
dc.relation.ispartof urn:issn:0030-6002
dc.title Hangsúlyeltolódások a hazai gyógyszerek finanszírozásában. A ritka betegségek kezelésére szolgáló árva gyógyszerek támogatása. Enzimpótló kezelések finanszírozása hazánkban
dc.type Journal Article 2015-11-26T13:28:20Z
dc.language.rfc3066 hu
dc.identifier.mtmt 2765531
dc.identifier.pubmed 25344850
dc.contributor.department SE/AOK/I/Genomikai Medicina és Ritka Betegségek Intézete
dc.contributor.institution Semmelweis Egyetem
dc.mtmt.swordnote TT: [Focus shifts in the Hungarian reimbursement system. Funding of orphan medicinal products for rare disease patients in Hungary: Financing of orphan medicines]

Files in this item



This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account